Effect of the Cannabinoid Receptor-1 Antagonist Rimonabant on Inflammation in Mice With Diet-Induced Obesity

CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice

(2010) T. Jourdan et al.   DIABETES

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

CD11c Expression in Adipose Tissue and Blood and Its Role in Diet-Induced Obesity

(2009) Huaizhu Wu et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects

(2009) Vincenzo Di Marzo et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition

(2009) A H Koolman et al.   INTERNATIONAL JOURNAL OF OBESITY

CB1 antagonists for obesity—what lessons have we learned from rimonabant?

(2009) Vincenzo Di Marzo et al.   Nature Reviews Endocrinology

The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets

(2009) Lisa Getty-Kaushik et al.   Obesity

Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism

(2009) Daniela Cota et al.   Obesity

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

(2008) Jean-Pierre Després et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats

(2008) A Schäfer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Ablation of CD11c-Positive Cells Normalizes Insulin Sensitivity in Obese Insulin Resistant Animals

(2008) David Patsouris et al.   Cell Metabolism

Endocannabinoid system in food intake and metabolic regulation

(2008) David Jesudason et al.   CURRENT OPINION IN LIPIDOLOGY

The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in Endocannabinoids

(2008) T. M. D'Eon et al.   DIABETES

Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant

(2008) A W Herling et al.   INTERNATIONAL JOURNAL OF OBESITY

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

(2008) Douglas Osei-Hyiaman et al.   JOURNAL OF CLINICAL INVESTIGATION

Cannabinoid Type 1 Receptor: Another Arrow in the Adipocytes’ Bow

(2008) L. Bellocchio et al.   JOURNAL OF NEUROENDOCRINOLOGY

Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells

(2008) V. L. Hegde et al.   MOLECULAR PHARMACOLOGY

Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet

(2008) Katarzyna M. Starowicz et al.   Obesity

The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure

(2008) Aaron N.A. Verty et al.   Obesity

Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats

(2007) T Croci et al.   BRITISH JOURNAL OF PHARMACOLOGY